GlassScriptPhysician profile
Alexander John Schlitt
NPI 1285137224
$2,888.36
in general payments reported to CMS, 2019-2025
30 companies · $1,252 in 2025
The $1,252 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $645 · 2024: $991 · 2025: $1,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,230 · Education: $549 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,229.95 |
| Education | $548.87 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $109.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $354.68 | 2025 | Onivyde |
| Incyte Corporation | $277.27 | 2023-2025 | Jakafi, Monjuvi, Zynyz |
| Rigel Pharmaceuticals, INC. | $224.64 | 2023-2024 | Rezlidhia, Tavalisse |
| Janssen Biotech, INC. | $220.90 | 2023-2025 | Darzalex, Tecvayli, Talvey |
| Daiichi Sankyo INC. | $199.39 | 2023-2025 | Vanflyta, Enhertu |
| Sobi, INC | $189.45 | 2023-2025 | |
| Pfizer INC. | $183.80 | 2023-2025 | |
| Genzyme Corporation | $115.17 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2023 | |
| Tempus Ai, INC | $99.30 | 2025 | Xt Cdx |
| Abbvie INC. | $98.00 | 2023 | Venclexta |
| Astrazeneca Pharmaceuticals LP | $85.98 | 2024-2025 | Enhertu, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $85.75 | 2024 | Opdivo |
| Genentech USA, INC. | $69.24 | 2023 | Phesgo, Alecensa, Perjeta |
| Takeda Pharmaceuticals U.S.A., INC. | $69.16 | 2024-2025 | Livtencity, Alunbrig |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $65.88 | 2024 | Cosela |
| Geron Corporation | $65.34 | 2025 | Rytelo |
| Merck Sharp & Dohme LLC | $45.01 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Gilead Sciences, INC. | $39.64 | 2023-2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $39.40 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.34 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $37.25 | 2025 | Libtayo |
| Blueprint Medicines Corporation | $32.36 | 2024 | Ayvakit |
| Beigene USA, INC. | $28.90 | 2025 | Brukinsa |
| Kite Pharma, INC. | $26.30 | 2025 | Yescarta |
| Fresenius Kabi USA, LLC | $25.20 | 2023 | Stimufend |
| Deciphera Pharmaceuticals INC. | $22.28 | 2025 | Qinlock, Romvimza |
| Eisai INC. | $17.43 | 2025 | |
| Lilly USA, LLC | $16.12 | 2025 | Jaypirca, Verzenio |
| Apellis Pharmaceuticals, INC. | $15.23 | 2023 | Empaveli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Schlitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.